Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effectiveness and Safety of Tixagevimab-Cilgavimab for COVID-19 Prevention in Chronic Dialysis Patients
TCTR20221031004Phase 4Completed
- Sponsor
- Faculty of Medicine Ramathibodi Hospital, 366 Mahidol University (Funding No.: RF_66023)
- Start
- Nov 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of tixagevimab + cilgavimab in coronavirus disease 2019 (COVID-19), sponsored by Faculty of Medicine Ramathibodi Hospital, 366 Mahidol University (Funding No.: RF_66023). Started Nov 2022; status: completed.
02
Drugs
tixagevimab + cilgavimab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on TCTR20221031004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20221031004.